From non-specific biomarker to targeted action: transdiagnostic and sex-specific drivers of high-CRP status in severe mental illness across the FondaMental Advanced Centers of Expertise (FACE) cohorts.

Fiche publication

Date publication

janvier 2026

Journal

Brain, behavior, and immunity

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HAFFEN Emmanuel

Tous les auteurs :
Rietberg T, Barbosa S, Meysman P, Aouizerate B, Bellivier F, Berna F, Capdevielle D, Chereau I, Courtet P, Dondé C, Dubertret C, Etain B, Hage WE, Gerentes M, Holtzmann J, Fakra E, Haffen E, Bouaziz N, Lefrere A, Llorca PM, Mallet J, Misdrahi D, Olié E, Pelletier A, Piva G, Pignon B, Polosan M, Rey R, Roux P, Samalin L, Schürhoff F, Schwan R, Stephan F, Szekely D, Urbach M, Vaiva G, Very E, Yrondi A, Leboyer M, Picker L, Godin O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41621630

Résumé

Low-grade systemic inflammation contributes to the pathophysiology of severe mental illness (SMI) in a substantial subset of patients, who often experience greater disease burden and poorer treatment response. Elevated C-reactive protein (CRP), defined as CRP ≥ 3 mg/L, has been proposed to identify this group, but its non-specificity limits the biomarker's ability to guide targeted intervention. We aimed to determine the most consistent drivers of high CRP across bipolar disorder (BD), schizophrenia (SZ) and major depressive disorder (MDD), and to translate these into clinically actionable intervention targets using robust data-driven methods.